China’s NMPA clears HBM-7575 to enter clinic in atopic dermatitis

March 9, 2026

Harbour Biomed Ltd. and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. have announced IND approval by China’s National Medical Products Administration (NMPA) for HBM-7575 (SKB-575) for the treatment of atopic dermatitis.

BioWorld Science Regulatory Dermatologic Bispecific antibody China NMPA

Today's news in brief

BioWorld

BioWorld briefs for May 15, 2026.

Illustration of a glowing circle to represent circRNA

ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

BioWorld

Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...

Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal

BioWorld

In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...

3D illustration of adeno-associated viruses

ASGCT 2026: Uncovering the mechanisms of AAV toxicity

BioWorld

Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...

Roche secures CE mark for Alzheimer’s blood test

BioWorld

Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...